Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToPPS: Pemetrexed Combinations in PS 2 NSCLC
NCT00892710Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jun 2009
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00892710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00892710.